| Delgado, Juan |
DURATIOM, NCT05294796: Efficacy and Safety of Antimicrobial Durations Treatment of Infections Associated With Osteosynthesis Material |
|
|
| Recruiting | 3 | 364 | Europe | Short course of antibiotherapy, Long course of antibiotherapy | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Infections | 10/24 | 04/26 | | |
ASTARTÉ, NCT04478721: Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins |
|
|
| Recruiting | 3 | 334 | Europe | Temocillin, Meropenem | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Spanish Network for Research in Infectious Diseases, SCReN Spanish research Network- CTU-HUVR | Bacteremia | 03/25 | 12/25 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
| Recruiting | N/A | 900 | Europe | Non-impositive Program for Optimizing the Use of Antimicrobials | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Bacterial Infections, Fungal Infection | 12/20 | 12/22 | | |
NCT04801862: Natural History of Clostridioides Difficile Infection |
|
|
| Recruiting | N/A | 750 | Europe | | Hospital Universitario de Valme | Clostridium Difficile Infection, Health Care Associated Infection, Nosocomial Infection | 06/24 | 12/24 | | |
| Recruiting | N/A | 2084 | Europe | Chorionic biopsy and peripheral blood collection in cases group, Chorionic biopsy and peripheral blood collection in control group | Carlos Simon Foundation | Preeclampsia | 06/26 | 06/26 | | |
| Active, not recruiting | N/A | 9585 | Europe | Peripheral blood collection in cases group, Peripheral blood collection in control group | iPremom | Preeclampsia | 03/24 | 10/24 | | |
| Active, not recruiting | N/A | 90 | Europe | Echocardiogram, Cardiac magnetic resonance, Coronary angiography, Endomyocardial biopsy | Juan Francisco Delgado Jimenez, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III | Transplant Failure, Heart Transplant Rejection, Antibody-mediated Rejection | 09/24 | 09/29 | | |
| Caro, Reyes Bernabe |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
LUNAR-4, NCT06558799: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 69 | Europe | NovoTTF-200T, Pembrolizumab | NovoCure GmbH | Non-Small Cell Lung Cancer (NSCLC) | 06/26 | 10/26 | | |
ICARS, NCT06219317: Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC |
|
|
| Recruiting | 2 | 136 | Europe | Cemiplimab, Placebo | European Organisation for Research and Treatment of Cancer - EORTC | NSCLC Stage IV | 01/30 | 01/30 | | |
KROCUS, NCT05756153: A Study of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation |
|
|
| Recruiting | 1/2 | 45 | Europe | GFH925, Cetuximab | Genfleet Therapeutics (Shanghai) Inc. | Advance Non-small Cell Lung Cancer | 03/25 | 08/25 | | |
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) |
|
|
| Active, not recruiting | 1/2 | 61 | Europe, Japan, US, RoW | M1774, Tuvusertib, Cemiplimab | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Non-Small Cell Lung Cancer | 05/25 | 02/26 | | |
SURPASS, NCT04044859: ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors |
|
|
| Recruiting | 1 | 120 | Europe, Canada, US | Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks | Adaptimmune, ICON plc | Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer | 12/25 | 04/37 | | |
|
|
ermEX-20, NCT05419700: A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion |
|
|
| Completed | N/A | 76 | Europe | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 09/23 | 09/23 | | |
